Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
| Autor: | Sinan Koca, Dincer Aydin, Melike Ozcelik, Faysal Dane, Mehmet Besiroglu, Bekir Hacioglu, Mustafa Karaca, Gamze Gokoz Dogu, Zeynep Oruç, Mehmet Bilici, Nihal B Kaplan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult Leiomyosarcoma Male medicine.medical_specialty Poor prognosis Indazoles medicine.medical_treatment Pharmacology toxicology Soft Tissue Neoplasms Targeted therapy Pazopanib 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Pharmacology (medical) In patient Protein Kinase Inhibitors Retrospective Studies Sulfonamides business.industry Soft tissue sarcoma Retrospective cohort study Sarcoma Middle Aged medicine.disease targeted therapy Survival Analysis Progression-Free Survival 030104 developmental biology Pyrimidines 030220 oncology & carcinogenesis soft tissue sarcoma Female business medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(3) |
| ISSN: | 1477-092X |
| Popis: | Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38–58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|